Reata Pharmaceuticals, Inc. (NASDAQ:RETA)‘s stock had its “buy” rating reissued by equities research analysts at Cowen and Company in a report issued on Tuesday.

The analysts wrote, “RETA reported 3Q17 financials yesterday, noting that the three major programs.””

RETA has been the topic of several other research reports. Citigroup Inc. reiterated a “buy” rating and issued a $87.00 target price (up previously from $39.00) on shares of Reata Pharmaceuticals in a research note on Tuesday, July 25th. Leerink Swann initiated coverage on Reata Pharmaceuticals in a report on Wednesday, September 13th. They issued an “outperform” rating and a $43.00 price target for the company. Jefferies Group LLC initiated coverage on Reata Pharmaceuticals in a report on Wednesday, August 30th. They issued a “buy” rating and a $44.00 price target for the company. ValuEngine downgraded Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Finally, Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $61.00 price target (up previously from $55.00) on shares of Reata Pharmaceuticals in a report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $54.71.

Reata Pharmaceuticals (NASDAQ RETA) traded down $2.37 on Tuesday, reaching $25.19. The company’s stock had a trading volume of 510,300 shares, compared to its average volume of 116,495. Reata Pharmaceuticals has a 52 week low of $18.51 and a 52 week high of $41.60. The company has a debt-to-equity ratio of -0.09, a quick ratio of 1.34 and a current ratio of 1.34.

Reata Pharmaceuticals (NASDAQ:RETA) last posted its earnings results on Monday, November 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.11). The business had revenue of $12.60 million during the quarter, compared to the consensus estimate of $12.54 million. The business’s revenue for the quarter was up .0% on a year-over-year basis. sell-side analysts predict that Reata Pharmaceuticals will post -1.73 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Reata Pharmaceuticals, Inc. (RETA) Rating Reiterated by Cowen and Company” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/11/14/reata-pharmaceuticals-inc-reta-rating-reiterated-by-cowen-and-company.html.

Several institutional investors have recently added to or reduced their stakes in RETA. Nationwide Fund Advisors lifted its holdings in shares of Reata Pharmaceuticals by 38.1% during the second quarter. Nationwide Fund Advisors now owns 4,368 shares of the company’s stock worth $138,000 after purchasing an additional 1,206 shares during the period. Wells Fargo & Company MN lifted its holdings in Reata Pharmaceuticals by 37.4% in the second quarter. Wells Fargo & Company MN now owns 5,591 shares of the company’s stock valued at $176,000 after acquiring an additional 1,521 shares during the period. First Allied Advisory Services Inc. acquired a new position in Reata Pharmaceuticals in the third quarter valued at approximately $203,000. The Manufacturers Life Insurance Company lifted its holdings in Reata Pharmaceuticals by 102.4% in the second quarter. The Manufacturers Life Insurance Company now owns 7,343 shares of the company’s stock valued at $233,000 after acquiring an additional 3,715 shares during the period. Finally, American International Group Inc. lifted its holdings in Reata Pharmaceuticals by 42.5% in the third quarter. American International Group Inc. now owns 7,528 shares of the company’s stock valued at $234,000 after acquiring an additional 2,247 shares during the period. 17.43% of the stock is owned by hedge funds and other institutional investors.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Analyst Recommendations for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.